Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LGD-4665 · 1 trial · 1 indication
Response was defined as platelet count \>= 50 x1000/uL for participants without Baseline steroid uses; or platelet counts \>= 50 x1000/uL and doubling the Baseline platelet counts for participants with baseline steroid uses. Confidence interval of response rate was computed using exact method of binomial proportion.
| Arm | Type | Description |
|---|---|---|
| LGD4665 | EXPERIMENTAL | LGD-4665: Experimental Thrombopoietin mimetic |
| Placebo | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| LGD-4665 | DRUG | LGD-4665 Thrombopoietin mimetic |
| Placebo | DRUG | Placebo |
Inclusion Criteria: * Adults 18 years or older * Diagnosis of ITP for at least 3 months consistent with ASH guidelines * Treated with one or more prior therapies for ITP and platelet counts \< 30,000/µL or \< 50,000/µL if on a stable oral corticosteroid for ≥ 4 weeks, supported by 2 platelet counts...
LGD-4665 is an investigational small molecule being studied for the treatment of immune thrombocytopenic purpura (ITP), a condition characterized by low platelet counts. It is in Phase 2 clinical development and is not yet approved by regulatory authorities.
LGD-4665 is being developed by GSK plc, a global biopharmaceutical company listed on the New York Stock Exchange under the ticker GSK. The drug is currently in Phase 2 clinical trials for immune thrombocytopenic purpura.
LGD-4665 is in Phase 2 clinical development. It is an investigational drug being evaluated for immune thrombocytopenic purpura (ITP) and has not received regulatory approval. One Phase 2 trial has been completed.
LGD-4665 has been studied in one completed Phase 2 clinical trial, identified as NCT00621894. This trial evaluated oral LGD-4665 versus placebo in adults with immune thrombocytopenic purpura (ITP) over six weeks, with an open treatment continuation phase.
LGD-4665 is not FDA approved. It is an investigational drug in Phase 2 clinical development for immune thrombocytopenic purpura (ITP). The completed trial NCT00621894 assessed its safety and efficacy, but the drug remains unapproved.